TELEhealth Shared Decision-making COaching for Lung Cancer Screening in Primary Care (TELESCOPE) for Hispanics

Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Aim 1: Culturally adapt the TELESCOPE intervention for Hispanics. Using iterative qualitative feedback from a study-specific Community Advisory Board, focus groups, and interviews with community members, the investigators will culturally adapt the TELESCOPE intervention for Hispanics at high risk for lung cancer. Aim 2: Assess the feasibility, acceptability, and implementation potential of the culturally adapted TELESCOPE intervention delivered by bilingual patient navigators for Hispanics. Hypothesis 1: The investigators expect a recruitment rate of ≥60%, ≥90% of Hispanic participants will complete the 1-week follow-up assessments, ≥80% of the key intervention components will be delivered with 80% fidelity by the patient navigators, and ≥90% of participants and clinicians will agree or completely agree that the intervention was feasible and acceptable. Aim 3: Explore the impact of a culturally adapted TELESCOPE intervention delivered by bilingual patient navigators vs enhanced usual care (EUC) on the initial uptake of low-dose computed tomography (LDCT) and quality of the shared decision-making (SDM) process. Hypothesis 2: The investigators expect that an adapted TELESCOPE intervention will result in higher uptake of LDCT and higher SDM quality for lung cancer screening (LCS) compared to EUC.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Maximum Age: 77
Healthy Volunteers: t
View:

‣ Aim 1 (Cultural Adaptation):

‣ To be eligible, patients must:

⁃ Identify as Hispanic and/or Latino(a)

⁃ Able to read and speak in English or Spanish

⁃ Be 50 to 77 years of age

⁃ Be a current or former smoker

⁃ Have at least a 20-pack-year smoking history

‣ Aims 2-3 (Pilot Randomized Controlled Trial)

‣ To be eligible, patients must:

• Identify as Hispanic or Latino(a)

• Able to speak and read in English or Spanish

• Be 50 to 77 years of age

• Be a current or former smoker having quit within the past 15 years

• Have at least a 20 pack-year smoking history

• Be scheduled for a non-acute care visit at one of the study sites.

• Not coughing up blood in the last two weeks

‣ Interviews

‣ Providers completing the semi-structured interviews will be:

• A practicing primary care clinician or a clinic director (n=20), nursing director, or clinic practice administrator at one of the participating sites, or a TELESCOPE study patient navigator and nurse navigator

• Age 18 or older

• Fluent in English

‣ Online surveys

‣ Providers completing online PRISM construct surveys will be:

• A practicing primary care provider at one of the participating sites or a TELESCOPE study navigator

• Age 18 or older

• Fluent in English

Locations
United States
New Jersey
Rutgers Cancer Institute
RECRUITING
New Brunswick
Contact Information
Primary
Evelyn Arana, DrPH
earana@cinj.rutgers.edu
9086420861
Backup
Arlette Chavez-Iniguez, MD
ac2758@CINJ.Rutgers.edu
(732)715-4923
Time Frame
Start Date: 2025-09-11
Estimated Completion Date: 2027-06-30
Participants
Target number of participants: 91
Treatments
Experimental: TELESCOPE intervention
Participants will be surveyed at baseline and at one-week after the scheduled primary care office visit. If a participant is a current smoker then they are offered and navigated to evidence-based smoking cessation. If the participant is interested in screening, an LDCT is ordered. Support for screening, diagnostic testing and oncology care will be provided as needed from the Nurse Navigators.
No_intervention: Enhanced Usual Care
Participants will be surveyed at baseline and at one-week after the scheduled primary care office visit. Primary and secondary outcome data related to the office visit will be collected.
Related Therapeutic Areas
Sponsors
Leads: Rutgers, The State University of New Jersey
Collaborators: New Jersey Commission on Cancer Research

This content was sourced from clinicaltrials.gov